EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis

Li Xu iD, Shanshan Chen iD, Haijun Cao iD, Zemin Feng iD, Chao Yang iD

Acta Pharmaceutica · 2024

DOI: 10.2478/acph-2024-0019 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Acta Pharmaceutica, 2024. Verfasst von Li Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chi…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This meta-analysis aimed to evaluate the efficacy of sorafenib plus transcatheter arterial chemoembolization (TACE) in treating hepato-cellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Twelve randomized controlled trials published until 28 th Sep 2022 were finally included. Of the total 1746 patients, of whom 458 received sorafenib and TACE treatment (Group S+TACE), and 1288 only underwent TACE (Group TACE), were enrolled. Outcomes including time to progression (TTP), objective response rate (ORR), disease control rate (DCR), overall survival (OS), survival rate (SR), and adverse reactions, were extracted. The OS (HR: 0.596, 95 %CI: 0.507–0.685, p < 0.001; I2 = 0.0 %) and TTP (HR: 0.379, 95 %CI: 0.205–0.553, p < 0.001; I 2 = 4.5 %) in the S+TACE group were longer than those in the TACE group. The ORR (RR: 2.101, 95 %CI: 1.555–2.839, p < 0.001; I2 = 0.0 %), DCR (RR: 1.547, 95 %CI: 1.126–2.126, p = 0.007; I2 = 79.6 %) and SR (RR: 1.416, 95 %CI: 1.183-1.694, p < 0.001; I 2 = 83.8 %) in the S+TACE group were higher than those in the TACE group. Compared with the TCAE group, the higher odds of HFSR, oral ulcer, and diarrhea among patients with HCC complicated by PVTT were discovered in the S+TACE group. The marginal significance was found in ascites and gastrointestinal bleeding between the two groups. Sorafenib plus TACE has good efficacy and mild adverse reactions, which may be worthy of clinical promotion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsPortal VeinSorafenibVenous ThrombosisHumansCombined Modality TherapyRandomized Controlled Trials as TopicSurvival RateTreatment Outcome

Stichwörter der Autor:innen

hepatocellular carcinomaportal vein tumor thrombosissorafenibtranscatheter arterial chemoembolization

Substanzen

Antineoplastic AgentsSorafenib

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou 310000, China.
  • Department of Orthopedics 903rd Hospital of PLA Hangzhou 310000, China.

ORCID-Profile: Li Xu, Shanshan Chen, Haijun Cao, Zemin Feng, Chao Yang

Zitieren

APA

Xu, L., Chen, S., Cao, H., Feng, Z., & Yang, C. (2024). Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis. Acta Pharmaceutica. https://doi.org/10.2478/acph-2024-0019

Vancouver

Xu L, Chen S, Cao H, Feng Z, Yang C. Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis. Acta Pharmaceutica. 2024. doi:10.2478/acph-2024-0019

BibTeX
@article{Xu2024,
  author = {Xu, Li and Chen, Shanshan and Cao, Haijun and Feng, Zemin and Yang, Chao},
  title = {Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis},
  journal = {Acta Pharmaceutica},
  year = {2024},
  doi = {10.2478/acph-2024-0019}
}
Kostenlos starten →